1. Home
  2. CRIS vs ACXP Comparison

CRIS vs ACXP Comparison

Compare CRIS & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Curis Inc.

CRIS

Curis Inc.

HOLD

Current Price

$0.46

Market Cap

976.1K

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

SELL

Current Price

$0.93

Market Cap

5.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CRIS
ACXP
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
976.1K
5.8M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
CRIS
ACXP
Price
$0.46
$0.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
★ $30.33
$10.33
AVG Volume (30 Days)
★ 5.8M
88.6K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.57
N/A
EPS
N/A
★ N/A
Revenue
★ $9,898,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$604.76
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 31.50
N/A
52 Week Low
$0.33
$0.90
52 Week High
$2,880.00
$7.54

Technical Indicators

Market Signals
Indicator
CRIS
ACXP
Relative Strength Index (RSI) 29.68 31.14
Support Level $0.33 N/A
Resistance Level $1.60 $1.12
Average True Range (ATR) 0.22 0.08
MACD 0.19 -0.00
Stochastic Oscillator 4.60 13.01

Price Performance

Historical Comparison
CRIS
ACXP

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: